China’s State Food and Drug Administration (SFDA) is poised to embrace a new era of transparency with the announcement of its forthcoming measures by Shao Mingli, the agency’s head. Scheduled for the second half of 2007, the SFDA is preparing to initiate regular press conferences, a proactive step designed to invite enhanced public and media scrutiny.
Complementing this initiative, a groundbreaking personnel system reform has been unveiled. This reform mandates the rotation of officials in specific roles after a tenure of five years, with those in more senior positions expected to rotate every three years. The policy is particularly focused on key roles within the realms of evaluation, approval, licensing, certification, personnel, and accounting, recognizing their significance in the regulatory framework.
In a further bid to augment public and media supervision, Shao Mingli outlined the impending introduction of a novel system. This system will establish specialist panels and clearly assign responsibilities, thereby enabling the public to effectively evaluate the duties and performance of SFDA officials.
